Elizabeth Anderson: Hi, guys. Thanks so much for the question. I was wondering if you could talk through how you’re thinking about the potential impact of 340b, maybe both on the core U.S. Pharmacy Business and sort of what the potential impact could be there, but then also if you could temporarily talk about how you’re thinking about the potential opportunity in fiscal ‘24 from Shield in that business? Thanks.
Rick Gates: Yes. This is Rick, and I’ll start and see if John wants to add — join me here. But, you know, as you look at 340b, we are very comfortable with our prior guidance and do expect 340b to actually be a slight up in production year-over-year in fiscal ‘23. Current assumptions still taking into the account latest manufacturer actions and restrictions. I think there’s three things to think about as we look at Q4 is that we do know, obviously, in headline of site since October and the continued developments and restrictions and litigation that can negatively impact the business itself. However, we are working with covered entities, who are starting to share data back in a more proactive way, which is opening up their impact to continue to get 340b value back to the government entities.
And third, we continue to work very proactively in the marketplace with covered entities that are still very active and signed up for us as a contract pharmacy. So we do think that we can offset some of the headwinds as we’re looking at it, but do still see a good line of sight into what we projected for this year, which is about slight growth. And John, I don’t know if you want to add?
John Driscoll: You know, I think the Shields is actually turns out to be an advantage position, because it’s not in the contract pharmacy business. It’s really a specialty pharmacy services business for hospital based 340b-related specialty pharmacies. And we continued to see strong demand and the sustainability of those contracts. And so we’re highly confident that Shields is actually in a great position, because of the just core growth of specialty pharmacy drugs and the need for hospitals to partner with a services platform that delivers a best-in-class adherence and integrates really well with hospitals that are needing to manage those high need chronic patients.
Operator: And your final question comes from the line of Eric Percher from Nephron Research. Your line is open.
Eric Percher: Thank you. It’s been difficult to piece together the U.S. Healthcare ramp from what was $350 million loss to significant profit next year. Now looking at $600 million to $650 million, can you tell us net of the actions you’re taking? How does fiscal year ‘24 look relative to the outlook six months ago when you closed? And then any insight on the contributions which businesses and how they’re coming together for the fiscal year ‘24 outlook?
James Kehoe: Yes. Eric, yes, the base here, so what we’re looking at here was the base here has come in about 300 light versus the original expectations set six months ago, and we’ve talked extensively about Summit and the — and some slowness at building patient panels at Village. And we have a series of actions to go address that. I think the best way you could model this out is versus the original goals. The year-on-year change we believe is absolutely intact. So you might want to think of it this way. We’re probably six to 12 months behind, but it will be in 2024. It’s unlikely we’ll recover the 300 loss in the base here. But the build year-on-year is in fact and probably we would do slightly more. John, is that a fair one?
